{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:20:24Z","timestamp":1768717224839,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81371055"],"award-info":[{"award-number":["81371055"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National clinical key construction project","award":["(2012) 649"],"award-info":[{"award-number":["(2012) 649"]}]},{"name":"Medical Science and Technology Development Project Fund of Nanjing","award":["ZKX 12047"],"award-info":[{"award-number":["ZKX 12047"]}]},{"name":"Medical Science and Technology Development Project Fund of Nanjing","award":["YKK13227"],"award-info":[{"award-number":["YKK13227"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bbrc.2015.08.014","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T09:05:13Z","timestamp":1438938313000},"page":"678-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder"],"prefix":"10.1016","volume":"465","author":[{"given":"Ling-Feng","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2015.08.014_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.bbrc.2015.08.014_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0065-2423(10)50006-4","article-title":"Ocular angiogenesis: mechanisms and recent advances in therapy","volume":"50","author":"Rajappa","year":"2010","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.bbrc.2015.08.014_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1196\/annals.1348.062","article-title":"Anti-VEGF aptamer (Pegaptanib) therapy for ocular vascular diseases","volume":"1082","author":"Ng","year":"2006","journal-title":"Ann. Ny. Acad. Sci."},{"key":"10.1016\/j.bbrc.2015.08.014_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.preteyeres.2003.08.001","article-title":"Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition","volume":"22","author":"Das","year":"2003","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.bbrc.2015.08.014_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10456-007-9068-y","article-title":"Ocular drug development-future directions","volume":"10","author":"Sherris","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2015.08.014_bib6","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.08.014_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2015.08.014_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2015.08.014_bib9","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2015.08.014_bib10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2015.08.014_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2015.08.014_bib12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2015.08.014_bib13","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1167\/iovs.13-13221","article-title":"Aberrant expression of long noncoding RNAs in early diabetic retinopathy","volume":"55","author":"Yan","year":"2014","journal-title":"Investig. Ophth. Vis. Sci."},{"key":"10.1016\/j.bbrc.2015.08.014_bib14","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1038\/cddis.2014.466","article-title":"Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus","volume":"5","author":"Liu","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2015.08.014_bib15","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1083\/jcb.200302047","article-title":"VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia","volume":"161","author":"Gerhardt","year":"2003","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.bbrc.2015.08.014_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.critrevonc.2005.12.003","article-title":"Regulation of angiogenesis by hypoxia-inducible factor 1","volume":"59","author":"Hirota","year":"2006","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.bbrc.2015.08.014_bib17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A\u00a0central role for inflammation in the pathogenesis of diabetic retinopathy","volume":"18","author":"Joussen","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2015.08.014_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1442-9071.2003.00645.x","article-title":"Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up","volume":"31","author":"Akarsu","year":"2003","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.bbrc.2015.08.014_bib19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archopht.1991.01080120077030","article-title":"Trabeculectomy with mitomycin: a comparative study with fluorouracil","volume":"109","author":"Kitazawa","year":"1991","journal-title":"Arch. Ophthalmol.-Chic."},{"key":"10.1016\/j.bbrc.2015.08.014_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000268016","article-title":"Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits","volume":"29","author":"Tilleul","year":"1997","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.bbrc.2015.08.014_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2007.04.044","article-title":"AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders","volume":"568","author":"Raghava","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2015.08.014_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions","volume":"34","author":"Klaassen","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.bbrc.2015.08.014_bib23","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1167\/iovs.10-6518","article-title":"Significance of outer blood-retina barrier breakdown in diabetes and ischemia","volume":"52","author":"Xu","year":"2011","journal-title":"Investig. Ophth. Vis. Sci."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15304046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15304046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:30:43Z","timestamp":1567038643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X15304046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0006291X15304046"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.08.014","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}